OSLO, Norway, November 7, 2012 /PRNewswire/ --
European Cancer Cluster Partnering (ECCP) 2012
ON SUNDAY, 11 NOVEMBER, representatives from the pharmaceutical industry, leaders in biotechnology and academic centres will descend on Hamburg, Germany, for a conference seeking to ease the "bench to bedside" transition. The 4th annual European Cancer Cluster Partnering event brings together a diverse and international community looking to develop market-ready innovations in oncology.
This year again, the European Cancer Cluster Partnering (ECCP) event will focus on "Building partnerships to accelerate innovation in oncology" and invites leaders in drug development to attend.
INNOVATION IN ONCOLOGY
To expand its public, ECCP2012 is organised as a satellite event of the European biotech industry autumn gathering BIO-Europe®, held in Hamburg 12 - 14 November.
The opening session will be dedicated to "Driving innovation in oncology: novel partnerships, clinical trials and financial models", and pharma leaders such as Sanofi , but also to world-class academic researchers and investors will address attendees.
The opening session will be followed by a company presentation session dedicated to innovative technology platforms. "Oncology partnering needs" will be addressed by MSD to provide an actualized view about licensing and external research strategies. A selection of "oncology startups to watch" will then be presented together with personalized medicine partnering opportunities.
TOP SPEAKERS ON DRUG DEVELOPMENT
The intensive one day event promises to deliver a forum of effective discussion on the potential opportunities in drug development and showcase the emerging products that can facilitate this growth. With years of experience in the pharmacology and biotech sectors, and with extensive knowledge on business development, Dr Sven Rohmann, Burrill & Company and David T Phillips, Partne
|SOURCE European Cancer Cluster Partnering(ECCP2012)|
Copyright©2012 PR Newswire.
All rights reserved